We have just published a MARA Rating for a preparative treatment used before stem cell transplants in blood cancers.

The clinical question: does this improve survival compared to the established standard? It does. Event-free survival improved from 50% to 64%. Overall survival improved from 56% to 71%.

The economic question: does it justify its cost?

NICE concluded it was cost-saving. More benefit at lower cost.

Two questions. Both answered clearly. Both pointing in the same direction.

That alignment is rare. It is also what makes a reimbursement decision straightforward.

Read the full MARA Rating here: https://mararating.com/report/treosulfan-for-preparative-conditioning-for-allogeneic-stem-cell-transplant-in-aml-mds-as-of-march-2026/